| Name | Title | Contact Details |
|---|
Katzke & Morgenbesser LLP is a boutique law firm specializing in a broad array of executive compensation-related matters. We have extensive experience representing senior corporate executives and other management employees, companies, boards of directors and compensation committees with respect to complex and sensitive employment, severance, retirement, consulting, equity and other incentive compensation arrangements. Such representations are often in connection with public and private business combinations, acquisitions and divestitures for corporations and partnerships. Each of our named partners has more than twenty-five years of experience in executive compensation. As former partners at major New York and international law firms, we are uniquely situated to provide independent, high quality, focused and responsive service without the likelihood of potential conflicts of interest. Our Firm counsels clients primarily with respect to executive compensation-related matters. We routinely provide consulting, drafting and negotiation guidance to individuals, companies, boards of directors and compensation committees on a wide range of topics, including the following areas: - Employment, Severance, Retention and Consulting Agreements - Non-Competition, Non-Solicitation and other Restrictive Covenants - Equity and Cash-based Incentive Compensation - Deferred Compensation Arrangements - Partnership Arrangements - Retirement Arrangements/SERPs - Rabbi Trusts and other Funding/Financing Vehicles - Change in Control Programs and Arrangements - Code Section Section 409A Reviews - Advisory Services to Boards of Directors and Compensation Committees
Dare to bank boldly and dream big. Whatever your dreams, its time to take your financial future to new heights. Were committed to helping you get there. Embold Credit Union is a local, member-owned, not-for-profit financial cooperative. That means when you join Embold, you become a member and an owner. All decisions we make keep your best interests at the forefront.
Turn 14 Distribution is a Performance Warehouse Distributor with distribution facilities strategically located in Hatfield, PA, Arlington, TX, Reno, NV, and Indianapolis, IN. Turn 14 Distributions strategy consists of catering to niche vehicle markets, along with stocking its partner manufacturers full product lines for quick order fulfillment. Exclusive Turn 14 Distribution promotions ensure that products are marketed efficiently and correctly to each suppliers target audience. The company relies upon its dedicated sales specialists—chosen for their experience in each particular market—to service its customers with superior knowledge. In addition, the companys website offers lens technology to permit customers to view the products available for each individual market most efficiently. Turn 14 Distributions up-to-the-minute online inventory tracking, efficient forecasting, and dedicated Customer Support Department allow the company to cut lead times and keep its customers informed about product fulfillment. The companys goal is to provide its customers the sales, marketing, and post-sales support needed to succeed in the modern marketplace. With 1,500,000 sq ft of modern distribution center space, Turn 14 Distribution boasts ground shipping coverage to 60% of the U.S. population in one day and 100% within two days. Globally, Turn 14 Distributions competitive freight rates, ship to your shop flat rate shipping, late shipping cutoff times, seven-day-a-week operation, and same day in-stock order fulfillment commitment enable it to service customers both across the United States and the world efficiently.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.